Carboplatin Equals Cisplatin: But How Do I Prescribe It?
- 1 September 2003
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 21 (17) , 3183-3185
- https://doi.org/10.1200/jco.2003.06.077
Abstract
No abstract availableThis publication has 29 references indexed in Scilit:
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- Lack of impact of platinum dose intensity on the outcome of ovarian cancer patientsEuropean Journal Of Cancer, 2003
- Carboplatin dosingEuropean Journal Of Cancer, 2002
- Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year ResultsJNCI Journal of the National Cancer Institute, 2000
- Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerNew England Journal of Medicine, 1996
- Prediction of Carboplatin Clearance From Standard Morphological and Biological Patient CharacteristicsJNCI Journal of the National Cancer Institute, 1995
- Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancerThe Lancet, 1992
- Serum Creatinine and Renal FunctionAnnual Review of Medicine, 1988
- Limitations of creatinine as a filtration marker in glomerulopathic patientsKidney International, 1985
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976